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Application of HPLC to the Isolation of
Molecular Targets in Dosimetry Studies
by Rod Balhorn,* J. A. Mazrimas,* and Michele Corzett*
High-performance liquid chromatography (HPLC) methods are described which permit the rapid iso-
lation ofmultiple target macromolecules from the tissues ofanimals exposed to chemical mutagens. DNA
and selected chromosomal proteins are isolated in a simple two step separation scheme. Isolated nuclei
are dissolved in 3 M guanidine hydrochloride and the DNA and chromosomal proteins separated on a TSK
3000 SW column. The DNA peak is retained for analysis and the chromatin proteins are dialyzed, lyo-
phylized, and rechromatographed on a PRP-1 column to separate individual histones. Hemoglobin and
albumin, two proteins that may prove useful for monitoring mutagen exposure, are isolated from 100 ,L
of blood by HPLC on a Poly Cat A cation exchange column.
Using this approach, we have monitored the kinetics and dose response ofadduct formation (and repair)
to DNA, histone, hemoglobin and albumin in mice exposed to 7-bromomethylbenzanthracene and
benzo[a]pyrene. The results of these studies are described and briefly discussed. Experiments with other
mutagens demonstrate the limits to which DNA adduct quantification may be pushed using radioisotopes.
Exposures to very high specific activity (200 Ci/mmole) benzo(a)pyrene have allowed DNA adduct quan-
tification down to a few adducts per cell.
Introduction
Exposure to genotoxic agents may be detected by a
variety of somatic and germinal assays in animals and
humans, but the biological significance ofthe observed
changes, as measured in vivo or in vitro, often remains
uncertain. One reason for this is that we cannot always
define the actual dose of chemical received by specific
target molecules. It is essential, therefore, that we de-
velop and routinely apply dosimetric techniques to-
gether with these bioassays. This will permit us to define
both the extent of damage sustained by specific target
molecules and the rate and efficiency ofdamage repair.
By employing dosimetric techniques that canbe applied
to any tissue, comparisons may be made relating dose
to different biological endpoints. Such studies would
also provide the common denominator (target dose) re-
quired for comparisons among species exposed to sim-
ilar substances.
One reason that dosimetry measurements are not
made anintegralpartofmostexposure/endpoint studies
is that target isolations and binding measurements are
often labor-intensive. Conventional methods for anal-
yses of DNA adduct formation, for example, require
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numerous steps to isolate and purify DNA prior to the
analysis ofbound DNA adducts. Another reason is that
few target molecules other than DNA have been ex-
tensively characterized with regard to their dose re-
sponse in exposed animals.
Recent improvements in high-performance liquid
chromatography (HPLC) and column packagings make
it possible to rapidly separate a variety ofmacromole-
cules from exposed animals. We have used HPLC to
facilitatetheisolationofselectedtargetmacromolecules
from the tissues ofmice exposed to radiolabeled chem-
ical mutagens and quantify the actual dose of chemical
thatinteractswiththesemolecules. Whiletheworkthat
is described here employs radiolabeled mutagens and
scintillation counting to quantify adduct formation, the
DNA and proteins provided by these separations may
also be analyzed by othertechniques that permit direct
analyses of adducts and do not require exposures to
radioactive compounds.
Isolation of Molecular Targets
The techniques described here emphasize the isola-
tion ofmacromolecules from two types oftargets: mol-
ecules that compose or are closely associated with the
genome(DNA, histone)andproteinsintheblood(hemo-
globin, albumin) that can be obtained easily and ana-BALHORN, MAZRIMAS, AND CORZETT
lyzed as dosimeters of recent chemical exposure.
While the ultimate target of mutagens and carcino-
gens is generally accepted to be DNA, other macrom-
olecules closely associated with DNA may also sustain
damage that alters the accessibility or genetic activity
ofspecificchromosomaldomains. Chromosomalproteins
such as the histones and high mobility group (HMG)
proteinsareintimately associatedwithDNAandappear
to modulate the packaging of the genome and its ac-
cessibility for transcription (1-3). The histones are syn-
thesized coincident with DNA replication and are as
stable, biochemically, as DNA itself (4-6). While the
HMG proteins, in contrast, do turn over (7,8), two of
these proteins appear to maintain genetically active re-
gions of the chromosome in an open, accessible confor-
mation (2,3).
Othertargets ofpotentialinterestarehemoglobinand
serum albumin. Adduct formation to hemoglobin has
been considered foruse in dosimetry studies as ameans
ofmonitoring exposure dose (9-11). Albumin, a natural
scavenger and carrier of metals, ions, proteins, fatty
acids, antibiotics, sugars, lipids, hormones and avariety
ofother molecules in serum (12-14) should also be con-
sidered. These proteins are excellent nucleophiles, and
both maybeisolated fromblood inreasonable quantities.
DNA Isolation by Gel Permeation
Chromatography
DNA and a number ofchromosomal proteins may be
isolated from tissue or cultured cells simultaneously.
The entire procedure requires approximately an hour
to perform and permits the isolation of from a few mi-
crograms to over a milligram of DNA per sample. If
both DNA and chromosomal proteins are to be isolated
from the same sample, a brief nuclear isolation step
must be performed to eliminate contaminating ribo-
somal and cytoplasmic proteins. Tissues (or cultured
cells) areVirtis-homogenized in amedium (grinding me-
dium: 0.25 M sucrose, 10 mM Tris, pH 8, 2.5 mM mag-
nesium chloride) which stabilizes the nuclear membrane,
and the nuclei are purified by centrifugation (10 min)
through 1 M sucrose containingthe detergent Triton X-
100. Afterrinsingingrindingmedium, thenuclearpellet
is dissolved in 3 M guanidine hydrochloride, sonicated
(to reduce DNA viscosity), and centrifuged to remove
insoluble material. If only DNA is to be isolated, the
nuclear isolation step may be eliminated and the cells
or tissues dissolved directly in 3 M guanidine
hydrochloride.
DNA and chromosomal protein are then separated by
chromatography ofthe dissociated nuclei on aTSK-3000
SWcolumn (three 7.5 mm x 300mmcolumns connected
intandem) in 1 Mguanidine hydrochloride, 50mMphos-
phate buffer pH 6.5. At a flow rate of 1.0 mL/min,
separation ofthe DNA and chromosomal protein peaks
(Fig. 1) is complete in less than 40 min. RNA, a minor
contaminant in these preparations (0.35%), elutes mid-
way between the DNA and protein peaks. By judi-
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FIGURE 1. Gel-permeation chromatography of dissociated nuclei.
HPLC ofdissociated mouse liver nuclei was performed on a TSK-
3000SW column in 1 M guanidine hydrochloride as described in
the text.
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FIGURE 2. Reverse-phase separationofhistonesand HMGproteins.
The lyophylized protein peak obtained following GPC chromatog-
raphy of dissociated nuclei was dissolved in 0.1% trifluoroacetic
acid and rechromatographed on a reverse-phase PRP-1 column.
Separation of the HMG proteins and individual histones was ac-
complished usingthefollowingmultistepacetonitrile gradient: 35-
68% buffer B, 8 min; 68-75% buffer B, 35 min; 75-100% buffer B,
4 min; 100% buffer B, 6 min; 100-35% buffer B, 1 min. Buffer A:
0.1% trifluoroacetic acid. Buffer B: 60% acetonitrile in 0.1% tri-
fluoroacetic acid.
ciously collecting only the early and midpoint (high
molecular weight) portion ofthe DNA peak, RNA con-
tamination of the DNA fraction may be virtually elim-
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inated. The DNA peak is processed directly, while the
protein peak must be dialyzed against water, lyophy-
lized and rechromatographed to separate specific
proteins.
DNA may be isolated from any cell or tissue by this
method. Recoveries of DNA and histone from the col-
umn typically exceed 95%. Only mammalian sperm re-
quire special treatment. The disulfide bridges in the
chromosomal proteins associated with the DNA in this
cell(protamine) mustfirstbereducedwithdithiothreitol
ormercaptoethanol and the chromatography performed
in 2 M guanidine hydrochloride. The protamines cannot
be dissociated from DNA without this reduction and
additional guanidine hydrochloride is required to keep
the protamine and DNA dissociated and soluble.
Reverse-Phase Separation of Chromosomal
Proteins
Further separation and isolation of specific histones
and nonhistone chromosomal proteins requires rechro-
matography of the protein peak on a reversed-phase
column. The lyophylized protein is dissolved in aqueous
trifluoroacetic acid (TFA, 0.1%) and injected into a 10
,um PRP-1 column (two 7.5 mm x 300 mm columns
connected in tandem; Hamilton Co., Reno, NE). Sep-
aration of the individual histones is accomplished by
using a multistep acetonitrile gradient (Fig. 2). The HMG
proteins elute early, just prior to Hi histone, while the
core mouse histones elute in the order H2B, H2A, H4,
and H3. Only the histones and HMG proteins are pres-
ent in sufficient quantities to allow analyses ofmutagen
binding at exposure levels which result in the formation
of less than one DNA adduct per 105 nucleotides.
Isolation of Hemoglobin and Albumin
Mouse hemoglobin and albumin are obtained by HPLC
ofwhole blood lysates. Aliquots ofmouse blood (100 ,uL)
are added to 1.0 mL sodium citrate (1%) and promptly
frozen at -20° C. After thawing and centrifuging, 0.5
mL samples are chromatographed on a 7.5 mm x 300
mm Poly Cat A cation exchange column (Custom LC,
Inc, Houston, TX) by using a multistep sodium chloride
gradient (Fig. 3). Under these conditions, albumin and
hemoglobin separate as individual peaks in less that 20
min. The hemoglobin peakis acomposite ofat least four
peaks; these represent sequence variants ofhemoglobin
that readily separate on this column.
FIGURE 3. Separation ofalbumin and hemoglobin from lysed mouse
blood. Whole mouse blood was added to 1.0 mL 1% sodium citrate
andpromptlyfrozen. Afterthawing, 500 ,uL waschromatographed
on a Poly Cat A cation exchange column by using the following
multistep sodium chloride gradient: 0% buffer B, 3 min; 0-40%
buffer B, 0.1 min; 40-60% buffer B, 10 min; 60% buffer B, 2 min;
60-0% buffer B, 1 min. Buffer A = 25 mM potassium phosphate,
pH 6. Buffer B = 0.3 M sodium chloride in 25 mM potassium
phosphate, pH 6.
Sample Processing
Following their isolation, the concentration of chro-
mosomal protein or DNA is determined from the ab-
sorbance ofthe sample at 230 nm or260 nm, respectively.
Albuminandhemoglobinconcentrations aredetermined
by using their absorbance at 280 nm. Absorbance mea-
surements are made directly on the DNA fractions or
blood proteins, while the chromosomal proteins are lyo-
phylized and redissolved in water. Each sample is then
extracted with ethyl acetate orwater-saturated butanol
to remove noncovalently bound mutagen. This step is
essential if adduct formation is to be quantified using
radiolabeled compounds and scintillation counting or
other techniques that do not differentiate hydrophobic
or electrostatic binding and the formation of covalent
adducts. Experiments with several different radiola-
beled mutagens have revealed that a substantial frac-
tion of the mutagen that coisolates with DNA is not
covalently bound to it (Table 1). This extractable mu-
tagen is tightly bound; extensive dialysis does not sig-
nificantly diminish the level of its binding.
Table 1. Mutagen binding in untreated and water-saturated butanol-extracted DNA and albumin samples.
DNA (adducts/nucleotide) Albumin (adducts/amino acid)
Unextracted Extracted Unextracted Extracted
7-BMBA 188/107 92/107 19.8/109 13.7/109
Benzo(a)pyrene 15.6/109 15.1/109 25.1/109 17.5/109
7,12-DMBA 53.1/109 34.4/109
TRP-P-2 126/107 17.5/107
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Applications
Because numerous macromolecules (DNA and a va-
riety ofproteins) may be isolated from the same cell or
tissue sample and separated by HPLC, this method is
particularly well suited for application in studies com-
paring the kinetics of adduct formation (and repair) to
multiple target molecules. Analyses of7-bromomethyl-
benzanthracene (7-BMBA) binding to mouse DNA, hi-
stone and albumin (Fig. 4), forexample, showthatpeak
adduct fornation is reached earlier in liver DNA than
either protein. The ma.jority ofthe DNA adducts (70%)
are removed within the first 24 hr, and 10% of the ad-
ducts persist for more than 30 days. Adduct formation
to histone H3 takes longer to peak, repair (or protein
replacement) occurs more slowly [other studies (15) have
shown that histones containing small adducts are not
turned over but that the adducts are removed; the
mechanisms for dealingwith large adducts (16,17) have
not yet been defined], and adduct removal approaches
completion. As with DNA, 7-BMBA adducts to serum
albumin are rapidly lost. In albumin, however, this re-
moval reflects the normal rapid turnover ofthe protein
(18) in mice (tl,2 = 1 day) and does not appeartoinvolve
repair.
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FIGURE 5. Dose-responseof7-bromomethylbenzanthraceneadduct
formationin mouseliverDNA, histone, andalbumin. MaleC57BL/
6 mice were exposed to 3H-7-BMBA by intraperitoneal injection
in dimethyl sulfoxide and sacrificed 2 hr later. DNA was isolated
from the livers of sham and exposed animals and processed as
described in the text. Albumin was isolated from 50 ,uL of blood
(lysed in l1o sodium citrate) by HPLC on a Poly Cat A cation
exchange column.
This technique has also been used to monitor the re-
lationship between exposure dose and the formation of
7-BMBA adducts to several different target macromo-
lecules in the mouse (Fig. 5). 7-BMBA is clearly more
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FIGURE 6. Dose-response of 7-bromomethylbenzanthracene bind-
ing to mouse hemoglobin. Hemoglobin was isolated from 50 ILL of
blood as described for albumin in Fig. 5.
reactive toward DNA than protein (chromosomal or
blood). Adduct binding to DNA (per nucleotide) is at
least 20-fold higher than to histone H3 (per amino acid)
and 4-fold higher than albumin. 7-BMBA binding to
hemoglobin is also observed (Fig. 6), but at a level ap-
proximately 20-fold lower than albumin. At low doses
of mutagen (below 5 nmole/g body weight), dose and
adduct formation in DNA, histone, albumin, and hemo-
globin are linearlyrelated. At higher doses this binding
plateaus in both albumin and hemoglobin and increases
nonlinearly in DNA and histone. The plateau observed
inalbuminandhemoglobinbinding appears torepresent
the saturation of 7-BMBA binding sites in blood. The
concomitant nonlinear increase in binding to chromo-
somal targets may reflect the proportionately larger
dose of7-BMBAreceivedbythesetargets oncethebulk
ofthe binding sites in hemoglobin and albumin become
saturated.
Mice exposed to benzo(a)pyrene at doses between 1
and 100 pmole/g body weight exhibit a linear relation
between exposure dose and albumin adducts (Fig. 7).
The observation that 7-BMBA adducts to albumin are
present in at least an order of magnitude greater con-
centration than hemoglobin adducts was also observed
with benzo[a]pyrene; hemoglobin binding was nearly
three orders ofmagnitude lower than albumin. The re-
sults with these two compounds suggest that albumin
binding may provide an extremely sensitive method for
monitoring mutagen exposure in short term experi-
ments. While albumin cannot, obviously, be considered
for monitoring exposures occurring over long periods
Table 2. Characteristic levels of DNA-adduct formation in mouse liver DNA following exposures to tritiated mutagens.
Specific activity, Amount injected/mouse Adducts/nucleotide
3H-Mutagen Ci/mmole ,umole cpm (liver DNA)
7-BMBA 0.55 0.18 2.2 x 108 6.9 per 106
TRP-P-2 1.5 0.15 3.0 x 108 4.0 per 107
Benzo(a)pyrene 25 2.9 x 10-3 0.8 x 108 1.4 per 108
7,12-DMBA 47 7.8 x 10-3 4.9 x 108 1.7 per 108
Benzo(a)pyrene 200 2.5 x 106 2.4 x i07 9.2 per 1011
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FIGURE 7. Dose-response of benzo(a)pyrene binding to hemoglobin and albumin. Male C57B1/6 mice were exposed to 3H-benzo(a)pyrene
(200 Ci/mmole) by intraperitoneal injection of the mutagen in dimethyl sulfoxide. Hemoglobin and albumin were isolated from 50 ,uL of
blood as described in the text: (0) albumin; (a) hemoglobin.
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FIGURE 8. Dose-response ofDNA-adduct formation in the liver of
mice exposed to 3H-benzo(a)pyrene. Mice were exposed as de-
scribed in Fig. 7. Liver DNA was isolated as described in the text
andthenumberofDNAadducts determined by scintillation count-
ing after extraction with equal volumes (three times) of water-
saturated butanol.
of time [the half-life of the albumin molecule in mice is
approximately 1 day (18) and 20 days in humans (19)],
its sensitivity does offer advantages for monitoring do-
simetry immediately after exposure.
The data shown in Table 2 illustrate how the quan-
tification ofDNA-adduct formation in in vivo studies is
limited by the specific activity of the radiolabeled mu-
tagen. In experiments with mutagens containing 1-25
Ci tritiumlmmole (the normal specific activity for most
tritium-labeled mutagens), we routinely detect the for-
mation of several DNA adducts per 107 or 10i nucleo-
tides. By increasingthe specific activity ofthe mutagen
8-fold, as with benzo(a)pyrene (specific activity of 200
Ci/mmole), we have been able to increase the detection
limit to a few adducts per cell (Fig. 8).
Conclusions
The HPLC techniques that we have described offer
a number of advantages over currently used methods
for target DNA and protein isolation. Using this ap-
proach, one can easily monitor and quantitate the bind-
ingofmutagensorcarcinogens tnvivotomultipletarget
molecules (DNA, histones, HMG proteins, albumin,
hemoglobin) within the same individual. The ease and
speed of sample processing allow the analysis of more
samplesthancanbehandledbycesiumchloridegradient
centrifugation or gel electrophoresis. The mild condi-
tions employed to dissociate and separate DNA and
chromosomal protein also minimize the loss of chemi-
cally unstable DNA adducts.
With this approach, analyses of DNA adduct forma-
tion require only a few tenths of a gram of tissue. If
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only DNA is to be isolated, the entire cell may be dis-
solved in guanidine hydrochloride and the DNA sepa-
rated from total protein by GPC. Using radiolabeled
mutagens, the sensitivity of the assay permits adduct
detection at the level of several adducts per cell. This
technique mayalsobecoupledwithmonoclonalantibody
or mass spectrometry methods for quantifying adduct
formation in vivo without the use of radioisotopes.
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